Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442007 | 0.67 | CCNK (0.37) | NOS3NOS1NOS2TYMS | |
| SCHEMBL18484200 | 0.64 | NUDT1 (0.43) | TYMS | |
| SCHEMBL9548473 | 0.60 | CYP2A6 (0.50) | NOS1TYMS | |
| SCHEMBL16056837 | 0.60 | CYP2A6 (0.43) | NOS3NOS1NOS2TYMS | |
| SCHEMBL11111047 | 0.57 | NR1H2 (0.56) | NOS1 | |
| SCHEMBL27563196 | 0.57 | ADORA2B (0.35) | TYMS | |
| SCHEMBL9036434 | 0.57 | — | — | |
| SCHEMBL8152934 | 0.56 | DUSP10 (0.39) | NOS3NOS1NOS2TYMS | |
| SCHEMBL11479924 | 0.56 | DDAH1 (0.46) | NOS1 | |
| SCHEMBL30849345 | 0.56 | DDAH1 (0.46) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2475666-A2 | GYRASE INHIBITORS | Trius Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NOS3 894/4885NOS1 1263/4885NOS2 1694/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NOS3 894/4885NOS1 1263/4885NOS2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.